Patent application number | Description | Published |
20090071855 | PACKAGING FOR AMORPHOUS STATINS AND COMPOSITIONS THEREOF - The present publication relates to a vacuum-sealed pack comprising an amorphous statin or a pharmaceutical composition thereof and at least one stabilizer such as, for example, an oxygen absorber, a moisture absorber or a combination thereof. | 03-19-2009 |
20090306173 | CRYSTALLINE FORMS OF ATORVASTATIN MAGNESIUM - The present invention relates to crystalline forms of Atorvastatin magnesium and processes for their preparation. The crystalline forms of the present invention are designated as form X, form Y, form Z and form P of atorvastatin magnesium. The present invention further relates to pharmaceutical compositions comprising form X, form Y, form Z and form P of atorvastatin magnesium and method of using the crystalline forms. | 12-10-2009 |
20120220777 | PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM OF LENALIDOMIDE - The present invention relates to an in-situ process for the preparation of polymorphic Form A of lenalidomide. | 08-30-2012 |
20120220783 | SALTS OF SUNITINIB - The present invention relates to salts of sunitinib and their preparation. | 08-30-2012 |
20120264789 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS - The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib. | 10-18-2012 |
20120271056 | PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM I OF L-MALIC ACID SALT OF SUNITINIB - The present invention relates to a process for the preparation of crystalline Form I of the L-malic acid salt of sunitinib. | 10-25-2012 |
20120302749 | PROCESSES FOR THE PREPARATION OF ERLOTINIB HYDROCHLORIDE FORM A AND ERLOTINIB HYDROCHLORIDE FORM B - The present invention relates to processes for the preparation of erlotinib hydrochloride Form A and erlotinib hydrochloride Form B. (I). | 11-29-2012 |
20130005777 | SORAFENIB ETHYLSULFONATE SALT, PROCESS FOR PREPARATION AND USE - The present invention provides sorafenib ethane sulphonate, process for its preparation, pharmaceutical composition comprising sorafenib ethane sulphonate and its use for the treatment of cancer. Formula (III). | 01-03-2013 |
20130005980 | PROCESS FOR THE PREPARATION OF SORAFENIB TOSYLATE - The present invention provides a process for the preparation of sorafenib tosylate, comprising contacting sorafenib free base with p-toluenesulphonic acid in water. | 01-03-2013 |
20130123511 | PROCESS FOR THE DIRECT PREPARATION OF MALIC ACID SALT OF SUNITINIB - The present invention relates to a process for the direct preparation of malic acid salt of sunitinib. | 05-16-2013 |
20130197242 | PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM II OF L-MALIC ACID SALT OF SUNITINIB - The present invention relates to stable crystalline Form II of L-malic acid salt of sunitinib and its preparation. | 08-01-2013 |
20130210865 | SORAFENIB DIMETHYL SULPHOXIDE SOLVATE - The present invention provides dimethyl sulphoxide solvate of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N | 08-15-2013 |
20130210885 | CRYSTALLINE FORMS OF L-MALIC ACID SALT OF SUNITINIB - The present invention relates to crystalline forms of L-malic acid salt of sunitinib and its preparation. The crystalline forms of the present invention are designated as Form V and Form VI of L-malic acid salt of sunitinib. Formula (I). | 08-15-2013 |
20130274478 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS - The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them, and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib. | 10-17-2013 |